NCT04407429 (VIVI) is a clinical trial of Laboratory Analyses in SARS-CoV-2, sponsored by Medical University of Vienna.

Who is sponsoring NCT04407429?

NCT04407429 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT04407429?

Interventions in NCT04407429: Laboratory Analyses.

What condition does NCT04407429 study?

NCT04407429 studies SARS-CoV-2, COVID-19.

Is NCT04407429 still recruiting?

NCT04407429 is currently status unknown. Last updated 29 May 2020.

Last reviewed 2020-05-29 · How we verify

NCT04407429: VIVI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vienna Versus SARS-CoV-2 Virus Study

Status unknown Last updated 29 May 2020

What this trial tests

trial testing Laboratory Analyses in SARS-CoV-2 in 12,000 participants. Status unknown.

Timeline

27 May 2020

Primary endpoint
27 June 2021

27 June 2021

Quick facts

Lead sponsor	Medical University of Vienna
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	12,000
Start date	27 May 2020
Primary completion	27 June 2021
Estimated completion	27 June 2021
Sites	1 location across Austria

Drugs / interventions tested

Laboratory Analyses

Conditions studied

SARS-CoV-2 — all drugs for SARS-CoV-2 →
COVID-19 — all drugs for COVID-19 →

Sponsor

Medical University of Vienna

Who can join

Eligibility, any sex, with SARS-CoV-2 or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examines the seroprevalence against SARS-CoV-2 in health care workers and patients at the Vienna General Hospital.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome.
Gyöngyösi M, Lukovic D, Mester-Tonczar J, Zlabinger K, et al · · 2023 · cited 6× · PMID 37773184 · DOI 10.1038/s41541-023-00739-2
Comparison of the prevalence of SARS-CoV-2 nucleoprotein antibodies in healthcare workers and an unselected adult and paediatric all-comer patient population: insights from a longitudinal study of healthcare workers and concurrent serial cross-sectional studies of patients at an
Riesenhuber M, Nitsche C, Binder CJ, Schernhammer ES, et al · · 2023 · cited 2× · PMID 36657754 · DOI 10.1136/bmjopen-2022-063760
Interruption of viral interference by anti-SARS-CoV-2 vaccination
Gyöngyösi M, Lukovic D, Tonczar JM, Zlabinger K, et al · · 2023 · DOI 10.21203/rs.3.rs-2627410/v1
Comparison of the Prevalence of SARS-CoV-2 Nucleoprotein Antibodies in Healthcare Workers and an Unselected Adult and Pediatric All-Comer Patient Population in Austria
Riesenhuber M, Nitsche C, Binder CJ, Schernhammer ES, et al · · 2022 · DOI 10.2139/ssrn.4072483
Österreichische Kardiologische Gesellschaft Jahrestagung 2022 : "Zurück in die Zukunft".
· 2022 · PMID 35608672 · DOI 10.1007/s00508-022-02035-w
Österreichische Kardiologische Gesellschaft Jahrestagung 2021 : "Alte Herzen - Neue Perspektiven".
· 2021 · PMID 34027582 · DOI 10.1007/s00508-021-01884-1

Verify or expand the search:

Other recruiting trials for SARS-CoV-2

Currently open trials in the same condition.

NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04407429 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 29 May 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04407429.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing